Literature DB >> 22753064

Prevalence of streptococci and increased polymicrobial diversity associated with cystic fibrosis patient stability.

L M Filkins1, T H Hampton, A H Gifford, M J Gross, D A Hogan, M L Sogin, H G Morrison, B J Paster, G A O'Toole.   

Abstract

Diverse microbial communities chronically colonize the lungs of cystic fibrosis patients. Pyrosequencing of amplicons for hypervariable regions in the 16S rRNA gene generated taxonomic profiles of bacterial communities for sputum genomic DNA samples from 22 patients during a state of clinical stability (outpatients) and 13 patients during acute exacerbation (inpatients). We employed quantitative PCR (qPCR) to confirm the detection of Pseudomonas aeruginosa and Streptococcus by the pyrosequencing data and human oral microbe identification microarray (HOMIM) analysis to determine the species of the streptococci identified by pyrosequencing. We show that outpatient sputum samples have significantly higher bacterial diversity than inpatients, but maintenance treatment with tobramycin did not impact overall diversity. Contrary to the current dogma in the field that Pseudomonas aeruginosa is the dominant organism in the majority of cystic fibrosis patients, Pseudomonas constituted the predominant genera in only half the patient samples analyzed and reported here. The increased fractional representation of Streptococcus in the outpatient cohort relative to the inpatient cohort was the strongest predictor of clinically stable lung disease. The most prevalent streptococci included species typically associated with the oral cavity (Streptococcus salivarius and Streptococcus parasanguis) and the Streptococcus milleri group species. These species of Streptococcus may play an important role in increasing the diversity of the cystic fibrosis lung environment and promoting patient stability.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22753064      PMCID: PMC3415522          DOI: 10.1128/JB.00566-12

Source DB:  PubMed          Journal:  J Bacteriol        ISSN: 0021-9193            Impact factor:   3.490


  32 in total

1.  Use of tuf sequences for genus-specific PCR detection and phylogenetic analysis of 28 streptococcal species.

Authors:  François J Picard; Danbing Ke; Dominique K Boudreau; Maurice Boissinot; Ann Huletsky; Dave Richard; Marc Ouellette; Paul H Roy; Michel G Bergeron
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

2.  Evaluation of universal probes and primer sets for assessing total bacterial load in clinical samples: general implications and practical use in endodontic antimicrobial therapy.

Authors:  H P Horz; M E Vianna; B P F A Gomes; G Conrads
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

Review 3.  The innate immune system in cystic fibrosis lung disease.

Authors:  R Bals; D J Weiner; J M Wilson
Journal:  J Clin Invest       Date:  1999-02       Impact factor: 14.808

4.  Use of 16S rRNA gene profiling by terminal restriction fragment length polymorphism analysis to compare bacterial communities in sputum and mouthwash samples from patients with cystic fibrosis.

Authors:  G B Rogers; M P Carroll; D J Serisier; P M Hockey; G Jones; V Kehagia; G J Connett; K D Bruce
Journal:  J Clin Microbiol       Date:  2006-07       Impact factor: 5.948

5.  Decade-long bacterial community dynamics in cystic fibrosis airways.

Authors:  Jiangchao Zhao; Patrick D Schloss; Linda M Kalikin; Lisa A Carmody; Bridget K Foster; Joseph F Petrosino; James D Cavalcoli; Donald R VanDevanter; Susan Murray; Jun Z Li; Vincent B Young; John J LiPuma
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-26       Impact factor: 11.205

6.  characterization of bacterial community diversity in cystic fibrosis lung infections by use of 16s ribosomal DNA terminal restriction fragment length polymorphism profiling.

Authors:  G B Rogers; M P Carroll; D J Serisier; P M Hockey; G Jones; K D Bruce
Journal:  J Clin Microbiol       Date:  2004-11       Impact factor: 5.948

7.  Quantitative real-time PCR using TaqMan and SYBR Green for Actinobacillus actinomycetemcomitans, Porphyromonas gingivalis, Prevotella intermedia, tetQ gene and total bacteria.

Authors:  Hiroshi Maeda; Chiyo Fujimoto; Yasuhiro Haruki; Takemasa Maeda; Susumu Kokeguchi; Millan Petelin; Hideo Arai; Ichiro Tanimoto; Fusanori Nishimura; Shogo Takashiba
Journal:  FEMS Immunol Med Microbiol       Date:  2003-10-24

Review 8.  Microbiology of airway disease in patients with cystic fibrosis.

Authors:  P H Gilligan
Journal:  Clin Microbiol Rev       Date:  1991-01       Impact factor: 26.132

Review 9.  Lung infections associated with cystic fibrosis.

Authors:  Jeffrey B Lyczak; Carolyn L Cannon; Gerald B Pier
Journal:  Clin Microbiol Rev       Date:  2002-04       Impact factor: 26.132

10.  Bacterial activity in cystic fibrosis lung infections.

Authors:  Geraint B Rogers; Mary P Carroll; David J Serisier; Peter M Hockey; Valia Kehagia; Graeme R Jones; Kenneth D Bruce
Journal:  Respir Res       Date:  2005-06-01
View more
  93 in total

1.  Cystic fibrosis mouse model-dependent intestinal structure and gut microbiome.

Authors:  Mark Bazett; Lisa Honeyman; Anguel N Stefanov; Christopher E Pope; Lucas R Hoffman; Christina K Haston
Journal:  Mamm Genome       Date:  2015-02-27       Impact factor: 2.957

Review 2.  The role of the bacterial microbiome in lung disease.

Authors:  Robert P Dickson; John R Erb-Downward; Gary B Huffnagle
Journal:  Expert Rev Respir Med       Date:  2013-06       Impact factor: 3.772

3.  Differential responses of human dendritic cells to metabolites from the oral/airway microbiome.

Authors:  K Whiteson; S Agrawal; A Agrawal
Journal:  Clin Exp Immunol       Date:  2017-03-21       Impact factor: 4.330

Review 4.  Enterosalivary nitrate metabolism and the microbiome: Intersection of microbial metabolism, nitric oxide and diet in cardiac and pulmonary vascular health.

Authors:  Carl D Koch; Mark T Gladwin; Bruce A Freeman; Jon O Lundberg; Eddie Weitzberg; Alison Morris
Journal:  Free Radic Biol Med       Date:  2016-12-16       Impact factor: 7.376

Review 5.  The Yin and Yang of Streptococcus Lung Infections in Cystic Fibrosis: a Model for Studying Polymicrobial Interactions.

Authors:  Jessie E Scott; George A O'Toole
Journal:  J Bacteriol       Date:  2019-05-08       Impact factor: 3.490

Review 6.  Cystic fibrosis respiratory microbiota: unraveling complexity to inform clinical practice.

Authors:  Lindsay J Caverly; John J LiPuma
Journal:  Expert Rev Respir Med       Date:  2018-09-03       Impact factor: 3.772

7.  Pseudomonas aeruginosa Can Inhibit Growth of Streptococcal Species via Siderophore Production.

Authors:  Jessie E Scott; Kewei Li; Laura M Filkins; Bin Zhu; Sherry L Kuchma; Joseph D Schwartzman; George A O'Toole
Journal:  J Bacteriol       Date:  2019-03-26       Impact factor: 3.490

8.  Tobramycin-Treated Pseudomonas aeruginosa PA14 Enhances Streptococcus constellatus 7155 Biofilm Formation in a Cystic Fibrosis Model System.

Authors:  Katherine E Price; Amanda A Naimie; Edward F Griffin; Charles Bay; George A O'Toole
Journal:  J Bacteriol       Date:  2015-10-19       Impact factor: 3.490

9.  HIV infection and microbial diversity in saliva.

Authors:  Yihong Li; Deepak Saxena; Zhou Chen; Gaoxia Liu; Willam R Abrams; Joan A Phelan; Robert G Norman; Gene S Fisch; Patricia M Corby; Floyd Dewhirst; Bruce J Paster; Alexis S Kokaras; Daniel Malamud
Journal:  J Clin Microbiol       Date:  2014-02-12       Impact factor: 5.948

10.  Coculture of Staphylococcus aureus with Pseudomonas aeruginosa Drives S. aureus towards Fermentative Metabolism and Reduced Viability in a Cystic Fibrosis Model.

Authors:  Laura M Filkins; Jyoti A Graber; Daniel G Olson; Emily L Dolben; Lee R Lynd; Sabin Bhuju; George A O'Toole
Journal:  J Bacteriol       Date:  2015-04-27       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.